Iida, Shinsuke http://orcid.org/0000-0002-4951-960X
Izumi, Tohru
Komeno, Takuya
Terui, Yasuhito
Chou, Takaaki
Ikeda, Takashi
Berg, Deborah
Fukunaga, Shinichi
Sugiura, Kenkichi
Sasaki, Makoto
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
https://doi.org/10.1007/s10147-021-02030-7
Funding for this research was provided by:
Takeda Pharmaceutical Co. Ltd.
Article History
Received: 2 June 2021
Accepted: 12 September 2021
First Online: 2 October 2021
Declarations
:
: Shinsuke Iida reports research funding, honoraria and fees from Takeda Pharmaceutical Company Limited, during the conduct of the study; Honoraria and fees from Ono, Celgene, Janssen, Sanofi, Daiichi Sankyo and Takeda Pharmaceutical Company Limited; research funding from AbbVie, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, GlaxoSmithKline, Ono and scholarship donations from Chugai, Kyowa Kirin, Ono, Sanofi and Takeda Pharmaceutical Company Limited, outside the submitted work. Takashi Ikeda reports honoraria and fees from Sanofi, outside the submitted work. Deborah Berg, Shinichi Fukunaga and Kenkichi Sugiura are employees of Takeda Pharmaceutical Company Limited, during the conduct of the study. Deborah Berg and Shinichi Fukunaga have stock ownership in Takeda Pharmaceutical Company Limited. Takaaki Chou has received honoraria from Takeda Pharmaceutical Company Limited, Ono, and BMS. Yasuhito Terui reports honoraria and fees from Celgene, Janssen, Merck Sharp & Dohme, Eisai, Ono, Takeda Pharmaceutical Company Limited, Chugai and AbbVie. Makoto Sasaki reports honoraria and lecture fees Takeda Pharmaceutical Company Limited. Tohru Izumi and Takuya Komeno have nothing to disclose.
: All study-related documents were reviewed and approved by the local or central institutional review boards of all study sites.
: Objectives and potential risks and benefits were explained to patients using the informed consent form approved by the institutional review board, with each patient having signed and dated the form before screening.